The Nasopharyngitis (Common Cold) drugs in development market research report provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Nasopharyngitis (Common Cold). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued products.

GlobalData tracks ten drugs in development for Nasopharyngitis (Common Cold) by eight companies/universities/institutes. The top development phase for Nasopharyngitis (Common Cold) is preclinical with four drugs in that stage. The Nasopharyngitis (Common Cold) pipeline has nine drugs in development by companies and one by universities/ institutes. Some of the companies in the Nasopharyngitis (Common Cold) pipeline products market are: Tris Pharma, Adare Pharma Solutions and Charleston Laboratories.

The key targets in the Nasopharyngitis (Common Cold) pipeline products market include Glycylpeptide N Tetradecanoyltransferase (Myristoyl CoA:Protein N Myristoyltransferase or Peptide N Myristoyltransferase or NMT or EC 2.3.1.97), Histamine H1 Receptor (HRH1), and Alpha 1 Adrenergic Receptor (ADRA1).

The key mechanisms of action in the Nasopharyngitis (Common Cold) pipeline product include Alpha 1 Adrenergic Receptor (ADRA1) Agonist with one drug in Phase II. The Nasopharyngitis (Common Cold) pipeline products include three routes of administration with the top ROA being Oral and one key molecule types in the Nasopharyngitis (Common Cold) pipeline products market including Small Molecule.

Nasopharyngitis (Common Cold) overview

Nasopharyngitis, also known as the common cold, is an infectious inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes, or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache, and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

For a complete picture of Nasopharyngitis (Common Cold)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.